| 证券代码 | BIAF.O |
| 证券名称 | bioAffinity Technologies Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2022-09-01 |
| 首发价格(元) | 6.125 USD |
| 首发数量(股) | 1282600 |
| 首发募资额(元) | 7,855,925.00 USD |
| 首发主承销商 | WallachBeth Capital, LLC |
| 货币单位 | USD |
| 公司名称 | bioAffinity Technologies, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 22211 West Interstate 10, Suite 1206, San Antonio, Texas, USA |
| 成立日期 | 2014-03-26 |
| 董事会主席 | Steven Girgenti |
| 公司属地 | United States 美国 |
| 公司网址 | www.bioaffinitytech.com |
| 电话 | +1 (210) 698-5334 |
| 传真 | - |
| 公司简介 | bioAffinity Technologies, Inc. focuses on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer therapeutics. The Company has developed a proprietary platform for in vitro diagnostics of which the first is a noninvasive test for early detection of lung cancer. The Company’s diagnostic tests are based on platform technologies that may be applicable to detecting other lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma, and diagnosing other types of cancer such as prostate and bladder cancers. |